Y-mAbs Therapeutics (YMAB) PT Lowered to $8 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Y-mAbs Therapeutics (YMAB) PT Lowered to $12 at BMO Capital
October 31, 2022 1:58 PM EDTBMO Capital analyst Etzer Darout lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $12.00 (from $29.00) while maintaining an Outperform rating.
The analyst commented, "The FDA AdCom's level of scrutiny on YMAB's BLA was a negative surprise for us. We're lowering our TP... More
